MSACL 2019 EU Abstract

Serum Biomarkers of Chemoradiosensitivity in Esophageal Cancer is Identified by the Targeted Metabolomics Approach

Seiji Fujigaki(1), Shin Nishiumi(1), Takashi Kobayashi(1), Masaru Yoshida(1, 2)
(1) Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, (2) A-MED, CREST, Tokyo, Japan

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Masaru Yoshida (Presenter) Kobe University Graduate School of Medicine >> POSTER (PDF)

Presenter Bio: Masaru Yoshida received his MD at Kobe University School of Medicine and received his MD in 1992 and worked in hospital as Gastroenterologist. He studied molecular biology at Kyoto University Graduate School of Medicine and received his PhD in 2000. He moved to Harvard Medical School and Brigham and Women’s Hospital. In 2005, he went back to Kobe University and started his metabolomics studies using Mass Spectrometry. He is currently a chief of Metabolomics Research at Kobe University and found several markers for the early detection in gastrointestinal cancers.

Relevant Financial Disclosures (within past 24 months) Grant/Research Support A-MED, CREST Conflict mitigation NOT REQUIRED.

Aim: To identify the serum metabolomics signature that is correlated with the chemoradiosensitivity of esophageal squamous cell carcinoma (ESCC).
Materials & Methods: Untargeted and targeted metabolomics analysis of serum samples from 26 ESCC patients, which were collected before the neoadjuvant chemoradiotherapy, were performed.
Results: On receiving the results of untargeted metabolomics analysis, we performed the targeted metabolomics analysis of the 6 metabolites (arabitol, betaine, glycine, L-serine, L-arginine, and L-aspartate). The serum levels of the 4 metabolites (arabitol, glycine, L-serine, and L-arginine) were significantly lower in the patients who achieved pathological complete response with neoadjuvant chemoradiotherapy compared with the patients who did not achieve pathological complete response (p=0.0086, 0.0345, 0.0106, and 0.0373, respectively).
Conclusion: The serum levels of metabolites might be useful for predicting the chemoradiosensitivity of ESCC patients.